Histone protein ubiquitination as a cancer biomarker
AssigneeNorthern Sydney Local Health District
InventorsDeborah Joy Marsh, Michael Anthony Hahn
Life of this patent
Estimating the term…
Abstract
The present disclosure relates generally to the field of cancer diagnosis. More specifically, the present disclosure relates to the identification and use of monoubiquitination of histone 2B as a biomarker for the diagnosis and prognosis of cancer including, but not limited to, parathyroid cancer. The present disclosure also relates to the identification of binding between CDC73 and RNF20, and the use of CDC73 and RNF20 in an assay for screening for an agent that modulates monoubiquitination of a histone protein.
Claims20
A method for diagnosing cancer in a subject, the method comprising measuring histone 2B protein monoubiquitination in a first cell of the subject, wherein decreased histone 2B protein monoubiquitination in said first cell compared to that of a second non-cancerous cell is diagnostic of cancer.
-22. (canceled)
A method of screening for an agent that modulates monoubiquitination of a histone protein, the method comprising determining whether a candidate agent reduces or augments binding between CDC73 and RNF20.
A method of screening for an agent that reduces or augments binding between CDC73 and RNF20, the method comprising:
- (i) administering a candidate agent to a first cell population comprising CDC73 and RNF20;
- (ii) analysing binding interactions between CDC73 and RNF20 in the first cell population;
- and
- (iii) comparing binding interactions analysed in (ii) with CDC73 and RNF20 binding interactions analysed in a second cell population to which the candidate agent has not been administered.
Dependencies are inferred from the claim text.